David J. Carlson, PhD, DABR, FASTRO, FAAPM

Current and Past Research Supported by:

Agency: National Institute of Health (NIH)
ID #: 1R21EB026553-01A1 (PI: Liu, W.)
Project: Tumor-targeted delivery and cell internalization of theranostic gadolinium nanoparticles for image-guided nanoparticle-enhanced radiation therapy
Role: Co-investigator

Agency: National Institute of Health (NIH)
ID #: 3UM1CA186689 (PI: LoRusso, P.)
Project: ViKTriY Early Clinical Trials Consortium
Role: Co-investigator

Agency: American Cancer Society (ACS)
ID #: 128352-RSG-15-197-01-TBG (PI: Bindra, R.)
Project: Pre-clinical development of Mibefradil as a novel glioma radiosensitizer
Role: Co-investigator

Agency: NIH/NIAID, The Dartmouth Physically-Based Biodosimetry Center for Medical Countermeasures Against Radiation (Dart-Dose CMCR) Pilot Program
ID #: Pilot grant from U19AI1091173 (Swartz, H.)
Grant Name: Comparing In Vivo biodosimetry with EPR to independent physical dosimetry methods
Role: PI

Agency: Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services
ID #: Subcontract #HHSO100201100024C from Dartmouth College
Project Name: In Vivo biodosimetry using electron paramagnetic resonance (EPR) spectroscopy
Role: PI

Agency: Yale Comprehensive Cancer Center (YCC)
Grant Name: Non-invasive imaging of tumor hypoxia in non-small cell lung cancer patients undergoing stereotactic body radiotherapy
Role: PI

Agency: American Cancer Society (ACS)
ID #: IRG-58-012-52
Grant Name: Modeling relative biological effectiveness and oxygen effects in x-ray, proton, and carbon ion radiotherapy
Role: PI